Randolph Seidler

Chief Executive Officer

2024 - Current

Co-Founder

2023

Co-Founder

2021

Member Of The Board Of Advisors

2019

Co-Founder

2019

Independent Board Director

2018

Outstanding veterinary gut health company.

Independent Board Director

2019 - 2022

Highly innovative vaccine platform company.

Venture Partner

2020 - 2022

VP, Global Head of Business Development & Licensing Animal Health

2017 - 2018

Responsible for licensing and acquisition of technology, pipeline projects and approved products for the Animal Health Business. Our global team partners with academic institutes, universities and companies of all sizes to bring innovative medicines and vaccines to our customers. In addition we ensure effective management of our strategic alliance partners.

Managing Director, BI Veterinary Research Center GmbH & Co. KG

2013 - 2017

Member of the BIVRC management board responsible for R&D.

VP, Global Head of R&D Animal Health

2007 - 2016

Globally responsible for identification, development and registration of new pharmaceutical and vaccine products for the Animal Health business. Managing all global activities relating to research, development, regulatory affairs, R&D QA and pharmacovigilance. Overseeing and managing an international R&D organization with major locations in the US, EU, China, Mexico and Japan. Responsible for developing and implementing the R&D strategy, including sites, technologies, pipeline, processes, external collaborations and human capital. As a member of the Animal Health Global Executive Management Board share overall responsibility for animal health business.

Head of Global R&D Site Integration Animal Health

2006 - 2007

Senior Principal Scientist Cardiovascular Diseases

2003 - 2006

Leading drug discovery projects (NCEs and NBEs) in the area of congestive heart failure and hypertension. Leading and managing a group of scientists (PhDs and junior scientist). Member of the Cardiovascular Drug Discovery Leadership team and of the Cardiovascular Clinical Expert Group (the senior leadership team for Cardiovascular Disease drug development). Part of the US post approval Medico-Marketing team for Pharmacology.

Principal Scientist Cardiovascular Diseases

2001 - 2003

Leading drug discovery projects (NCEs, NBEs and Gene Therapy) in the area of angiogenesis and acute myocardial infarction. Leading and managing a group of scientists (PhDs and junior scientist). Driving innovation by proposing and validating novel drug discovery targets and strong contribution to delineating a novel R&D strategy for Cardiovascular Disease drug discovery.

Senior Scientist General Pharmacology

1997 - 2000

Leading a laboratory in the area of cardiovascular physiology and pharmacology. Evaluating novel drug candidates with respect to cardiovascular safety and ancillary efficacy (hemodynamics and electrophysiology).